DTXM.F Stock Overview
Manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Deltex Medical Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.003 |
| 52 Week High | UK£0.43 |
| 52 Week Low | UK£0.0013 |
| Beta | 0.81 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.30% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| DTXM.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | -99.3% | 20.9% | 31.7% |
Return vs Industry: DTXM.F underperformed the US Medical Equipment industry which returned 9.3% over the past year.
Return vs Market: DTXM.F underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| DTXM.F volatility | |
|---|---|
| DTXM.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DTXM.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DTXM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 37 | Andy Mears | www.deltexmedical.com |
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; DoppLink, a patient interface cable that enhances signal processing; and PressureWave, a pulse contour analysis algorithm. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting; and TrueVue monitor.
Deltex Medical Group plc Fundamentals Summary
| DTXM.F fundamental statistics | |
|---|---|
| Market cap | US$3.31m |
| Earnings (TTM) | -US$1.66m |
| Revenue (TTM) | US$2.30m |
1.4x
P/S Ratio-2.0x
P/E RatioIs DTXM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DTXM.F income statement (TTM) | |
|---|---|
| Revenue | UK£1.78m |
| Cost of Revenue | UK£651.00k |
| Gross Profit | UK£1.13m |
| Other Expenses | UK£2.41m |
| Earnings | -UK£1.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00068 |
| Gross Margin | 63.34% |
| Net Profit Margin | -72.18% |
| Debt/Equity Ratio | 55.5% |
How did DTXM.F perform over the long term?
See historical performance and comparison